Efficacy and safety of MK ‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Priscilla A.
Hollander
MD
,
Wendy L.
Carofano
PharmD
,
Raymond L.H.
Lam
PhD
,
Gregory T.
Golm
PhD
,
Roy
Eldor
MD
,
Michael F.
Crutchlow
MD
,
Michael C.
Marcos
MS
,
Marc S.
Rendell
MD
,
Philip D.
Home
DPhil
,
Baptist
Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Insulin | Lantus | Obesity